MedTrace Logo

A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer

NCT00130728 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 636

Last updated 2021-01-14

Study results available
· View outcomes & findings →

Summary

This is a Phase III, multicenter, placebo-controlled, double-blind, randomized study. Approximately 650 patients will be randomized in a 1:1 ratio to one of two treatment arms.

Conditions

Interventions

DRUG

bevacizumab

intravenous infusion of bevacizumab at a dose of 15 mg/kg on the first day of each 3-week cycle

DRUG

erlotinib HCl

oral erlotinib HCl 150 mg/day orally

DRUG

placebo

intravenous infusion of placebo at a dose of 15 mg/kg on the first day of each 3-week cycle

Sponsors & Collaborators

  • Genentech, Inc.

    lead INDUSTRY

Principal Investigators

  • Clinical Trials · Genentech, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-08
Primary Completion
2008-07-15
Completion
2019-12-23

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00130728 on ClinicalTrials.gov